Tegavivint is under clinical development by Iterion Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tegavivint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tegavivint (BC-2059) is under development for the treatment of desmoid tumors, metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), acute myelocytic leukemia, multiple myeloma, solid tumors including osteosarcoma, r/r non-Hodgkin lymphoma and desmoid tumors, Ewing sarcoma, liver tumors (hepatocellular carcinoma [HCC] and hepatoblastoma), osteosarcoma, Wilms tumor, acute myeloid leukemia, colorectal cancer and idiopathic pulmonary fibrosis. The drug candidate is administered through oral and intravenous route. It is a small molecule anthraquinone oxime-analog. It acts by targeting transducin beta-like protein 1. It was also under development for cancer, pancreatic cancer, ovarian cancer, chronic myelocytic leukemia (CML, Chronic Myeloid Leukemia), myelodysplastic syndrome.
Iterion Therapeutics overview
Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company is headquartered in Houston, Texas, the US.
For a complete picture of Tegavivint’s drug-specific PTSR and LoA scores, buy the report here.